A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses-Reference-Cited by-同舟云学术

A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses

Published:2022-08-26 Issue:6 Volume:18 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Nistor Gabriel I.¹,Dillman Robert O.¹^ORCID,Robles Rockelle M.¹,Langford James L.¹,Poole Aleksandra J.¹,Sofro Muchlis A. U.²,Nency Yetty M.³,Jonny Jonny⁴,Yana Martina L.⁴,Karyana Mahammad,Lestari Endang S.⁵,Triwardhani Ria²,Mujahidah Mujahidah²,Sari Retty K.⁴,Soetojo Nur A.²,Wibisono Djoko⁴,Tjen Daniel⁴,Ikrar Taruna⁵,Sarkissian Gregory⁶,Winarta Haryono⁷,Putranto Terawan A.⁴,Keirstead Hans S.¹

Affiliation:

1. AIVITA Biomedical, Irvine, CA, USA

2. Dr. Kariadi Hospital, Semarang, Indonesia

3. Faculty of Medicine, Diponegoro University, Semarang, Indonesia

4. Gatot Soebroto Army Hospital (RSPAD), Jakarta, Indonesia

5. Ministry of Health Republic of Indonesia, Jakarta, Indonesia

6. PT AIVITA Biomedika Indonesia, Jakarta, Indonesia

7. PT Rama Emerald Multi Sukses, East Java, Indonesia

Funder

funding

Publisher

Informa UK Limited